1. Home
  2. MNMD vs VHI Comparison

MNMD vs VHI Comparison

Compare MNMD & VHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MNMD
  • VHI
  • Stock Information
  • Founded
  • MNMD 2019
  • VHI 1932
  • Country
  • MNMD United States
  • VHI United States
  • Employees
  • MNMD N/A
  • VHI N/A
  • Industry
  • MNMD Pharmaceuticals and Biotechnology
  • VHI Major Chemicals
  • Sector
  • MNMD Health Care
  • VHI Industrials
  • Exchange
  • MNMD Nasdaq
  • VHI Nasdaq
  • Market Cap
  • MNMD 509.2M
  • VHI 454.3M
  • IPO Year
  • MNMD N/A
  • VHI N/A
  • Fundamental
  • Price
  • MNMD $9.22
  • VHI $15.99
  • Analyst Decision
  • MNMD Strong Buy
  • VHI Sell
  • Analyst Count
  • MNMD 7
  • VHI 1
  • Target Price
  • MNMD $24.71
  • VHI $12.00
  • AVG Volume (30 Days)
  • MNMD 1.2M
  • VHI 13.3K
  • Earning Date
  • MNMD 11-06-2025
  • VHI 11-06-2025
  • Dividend Yield
  • MNMD N/A
  • VHI 1.96%
  • EPS Growth
  • MNMD N/A
  • VHI 269.89
  • EPS
  • MNMD N/A
  • VHI 3.44
  • Revenue
  • MNMD N/A
  • VHI $2,093,500,000.00
  • Revenue This Year
  • MNMD N/A
  • VHI $22.20
  • Revenue Next Year
  • MNMD N/A
  • VHI $7.66
  • P/E Ratio
  • MNMD N/A
  • VHI $4.74
  • Revenue Growth
  • MNMD N/A
  • VHI 4.04
  • 52 Week Low
  • MNMD $4.70
  • VHI $14.10
  • 52 Week High
  • MNMD $11.02
  • VHI $41.75
  • Technical
  • Relative Strength Index (RSI)
  • MNMD 47.40
  • VHI 44.80
  • Support Level
  • MNMD $8.70
  • VHI $15.56
  • Resistance Level
  • MNMD $9.30
  • VHI $16.74
  • Average True Range (ATR)
  • MNMD 0.58
  • VHI 0.70
  • MACD
  • MNMD -0.13
  • VHI -0.07
  • Stochastic Oscillator
  • MNMD 22.41
  • VHI 20.38

About MNMD Mind Medicine (MindMed) Inc.

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

About VHI Valhi Inc.

Valhi Inc is a holding company that provides chemicals, security products, waste management systems, and real estate development and management services through its subsidiaries. It operates its business in three segments, which are Chemicals, Component Products, and Real Estate Management and Development. The company derives maximum revenue from the Chemicals segment, which produces and markets value-added titanium dioxide pigments (TiO2). TiO2 is used to impart whiteness, brightness, opacity, and durability to various products, including paints, plastics, paper, fibers, and ceramics. Geographically, the company generates maximum revenue from the United States and also has a presence in Germany, Canada, Norway, and Belgium.

Share on Social Networks: